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ACTH-independent macronodular adrenal hyperplasia (AIMAH) is a rare 
cause of endogenous Cushing’s syndrome (CS). The diagnosis is suggested 
by bilateral adrenal nodular enlargement on conventional imaging and the 
demonstration of ACTH-independent hypercortisolism. Cortisol secretion 
in AIMAH can be regulated by the aberrant adrenal expression of receptors 
for gastric inhibitory polypeptide, vasopressin, catecholamines, luteinizing 
hormone/human chorionic gonadotropin and serotonin. We report on a 
47-year-old man with CS due to AIMAH. The cortisol levels were increased 
after vasopressin stimulation, suggesting aberrant expression of vaso-
pressin receptor in the adrenal glands. Total adrenalectomy is considered 
a standard therapy for AIMAH. [Tzu Chi Med J 2007;19(3):164–168]
 TZU CHI MED J  September 2007  Vol 19  No 3
*Corresponding author. Division of Endocrinology and Metabolism, Department of Internal 
Medicine, Buddhist Tzu Chi General Hospital, 707, Section 3, Chung Yang Road, Hualien, Taiwan.
E-mail address: duanmonk@tzuchi.com.tw
1. Introduction
Endogenous Cushing’s syndrome (CS) is a rare disease 
with an estimated incidence of 1 case per 500,000 
persons [1]. ACTH-independent macronodular adre-
nal hyperplasia (AIMAH) accounts for only 1% of CS 
cases [2]. Hyperplasia is characterized by an increase 
in the size and weight of the adrenal glands due to 
a non-malignant increase in the number of adreno-
cortical cells. The regulation of cortisol secretion in 
patients with AIMAH can be mediated by the aberrant 
expression of membrane receptors for gastric inhibi-
tory polypeptide (GIP), vasopressin, catecholamines, 
luteinizing hormone (LH)/human chorionic gonado-
tropin (hCG), and serotonin [3]. We present a case of 
AIMAH and demonstrate cortisol hypersecretion by 
vasopressin.
2. Case report
A 47-year-old man was referred to our hospital due 
to an incidental finding of huge bilateral adrenal 
masses on abdominal computed tomography scan 
after a traffic accident. He had hypertension for 
3 years and his regular medication included atenolol 
and valsartan. His older sister had adrenal disease 
and had surgery 10 years previously. His height was 
168 cm, weight was 68 kg and blood pressure was 
151/98 mmHg. There were mild degrees of a moon 
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face, nuchal hump, and central obesity, but no vio-
laceous striae, or ecchymoses. His serum potas-
sium was 4.2 mmol/L, and sodium was 140 mmol/L. 
The cortisol and ACTH levels were measured by kits 
(ADVIA Centaur®, Bayer Diagnostics, Dublin, Ireland; 
Immulite®/Immulite® 1000 ACTH, Diagnostic Products 
Corp., Los Angeles, CA, USA). The morning baseline 
plasma cortisol level was 24.19 μg/dL (reference 
range, 5–20 μg/dL), while the ACTH level was less 
than 10 pg/mL (reference range, 10–45 pg/mL). The 
24-hour urinary free cortisol (UFC) was markedly 
elevated to 550.8 μg/day (reference range, 20–90 μg/
day). Administration of both low and high doses of 
dexamethasone failed to suppress cortisol excretion 
(Table 1), establishing the diagnosis of autonomous 
hypercortisolism. Since abdominal computed tomogra-
phy showed bilateral adrenal macronodular masses 
(Fig. 1), the diagnosis was consistent with CS due to 
ACTH-independent macronodular adrenal hyperplasia.
In order to investigate the pathophysiology of the 
hyperfunction of this macronodular hyperplasia, a 
number of stimulation tests were performed. Each 
test was done in the morning with the patient in a 
supine position after overnight fasting. After obtaining 
baseline serum cortisol and ACTH, a stimulant was 
given (see below) on separate days and serum corti-
sol and ACTH levels were obtained every 30–60 min-
utes for 2–3 hours as specified by each test. There was 
no appreciable change in cortisol and ACTH levels 
after ingestion of a mixed meal, intravenous admini-
stration of 100 μg gonadotropin-releasing hormone 
(GnRH) or 1 mg glucagon, or oral administration of 
10 mg metoclopramide. However, after intravenous 
administration of 1 mg of arginine vasopressin, there 
was a prompt rise in serum cortisol while serum 
ACTH remained suppressed (Table 2 & Fig. 2).
3. Discussion
Cases of AIMAH are usually discovered either as an 
incidental radiological finding or during evaluation 
Table 1 — Biochemistry data
 Plasma cortisol  Plasma ACTH  UFC
 (μg/dL) (pg/mL) (μg/d)
Baseline 24.19 < 10 550.5
LDDST 30.29 ND ND
HDDST 21.92 ND ND
UFC = urinary free cortisol, normal < 100 μg/d; LDDST = low-dose 
dexamethasone suppression test, dexamethasone 0.5 mg per oral 
q6h for 2 days; HDDST = high-dose dexamethasone suppression 
test, dexamethasone 2 mg per oral q6h for 2 days; ND = no data.
Fig. 1 — Computed tomography scan of the adrenals demon-
strates bilateral adrenal macronodular masses (arrows).
Table 2 — Basal and stimulated serum cortisol levels in 
the patient*
 Cortisol (μg/dL)
 Basal After stimulus
Test  
  Fasting supine-upright 24.19 25.17
  Mixed meal 22.78 22.42
  Vasopressin 1 mg IV 23.79 45.83
  Metoclopramide 10 mg PO 24.01 24.26
  GnRH 100 mg IV 21.16 19.77
  Glucagon 1 mg IV 18.94 17.67
*A change of less than 25% in plasma cortisol was defined as no 
response, a 25–49% change was a partial response, and a change of 
50% or greater was a positive response. ACTH concentrations were 
less than 10 pg/mL both before and after all the stimulation tests.
Fig. 2 — Overproduction of cortisol by vasopressin stim-
ulation. The administration of 1 mg vasopressin rapidly 
increased plasma cortisol concentration, but there was 
no response to metoclopramide, gonadotropin-releasing 
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of adrenal hypersecretion syndrome, as in our case. 
It is an extremely rare cause of CS, and only occurs in 
1% of all cases of CS.
In AIMAH, the adrenal glands appear lobular. The 
architecture is often grossly distorted [4]. The radiologic 
features of AIMAH are bilateral adrenal masses with nod-
ules of soft tissue density, which are often larger than 
5 cm in diameter, and usually distort and completely 
obscure the normal adrenal glands [5]. Predominant 
enlargement of the unilateral adrenal gland is occasion-
ally observed in patients with AIMAH [6,7].
This syndrome has been reported in all ages 
[8], but most patients present in the fifth and sixth 
decades of life [9,10]. It appears to be equally dis-
tributed between males and females in contrast to 
the female predominance of pituitary/hypothalamic 
Cushing’s disease [9]. The majority of AIMAH cases 
occur sporadically but familial clustering with a sug-
gestion of an autosomal dominant pattern has been 
reported [11]. It is a benign process that has never 
been shown to have malignant potential [3]. In cases 
of hypercortisolism, plasma and urine cortisol con-
centrations are increased but plasma ACTH is sup-
pressed, as in our patient.
The mechanisms by which excessive cortisol is pro-
duced even in the face of suppressed ACTH were pre-
viously unknown, but it is now reasonably clear that 
it is likely driven by factors other than ACTH. These 
factors (hormones) escape cortisol-mediated nega-
tive feedback either by ectopic expression or hyper-
reaction to eutopically expressed membrane-bound 
receptors on the nodular cells and/or hyperplastic 
adrenal cortical cells. Hormones suspected of acti-
vating the aberrant receptors include GIP, vasopressin, 
catecholamines, LH and serotonergic 5-HT4 receptor 
effectors [12].
GIP- or food-dependent CS has been found in some 
patients with AIMAH [13,14]. The fact that cortisol pro-
duction in these cases was stimulated by orally admin-
istered glucose, and lipid- or protein-enriched meals, 
but not by intravenously administered glucose led 
to the speculation that GIP or aberrant GIP receptor 
expression on the cell membrane is involved in the 
mechanism of cortisol hypersecretion. Plasma corti-
sol levels correlated well with plasma GIP concentra-
tions during the various test meals. Our patient did 
not show a cortisol response to a mixed meal.
Vasopressin is mediated by stimulation of spe-
cific G protein-coupled receptors, classified into three 
sub types, V1-vascular, V2-renal and V3 (also named 
V1b)-pituitary vasopressin receptors [15–17]. Many 
pituitary corticotroph adenomas have been shown to 
increase ACTH release after administration of lysine-
vasopressin, and hence hypersecretion of cortisol 
[18]. But in adrenal CS, plasma cortisol should not be 
stimulated with administration of vasopressin as long 
as ACTH remains suppressed from the negative 
feedback mechanism. However, unexpected direct 
stimulation of cortisol secretion by exogenous 
arginine-vasopressin or lysine-vasopressin administra-
tion has been described in cases of adrenal CS [19], 
including unilateral adrenal adenomas, carcinomas 
and AIMAH. V1a-vasopressin receptor is expressed 
in the normal adrenal cortex and modulates mod-
est direct effects of vasopressin on steroidogenesis 
[20]. The exaggerated steroidogenic response to 
vasopressin, as in our patient, is best explained by 
increased activity of a “eutopic” receptor–effector 
system or aberrant receptor effect. Provocation tests 
in vivo indicated that arginine vasopressin promoted 
cortisol secretion through vasopressin V1a, V1b and 
V2 receptors [21].
It is well known that in addition to modulating 
aldosterone secretion, catecholamines stimulate the 
hypothalamic–pituitary–adrenal axis via activation 
of α1-adrenoreceptors in the paraventricular nuclei 
leading to corticotropin-releasing hormone release and 
subsequent increased plasma levels of ACTH as well 
as cortisol [22]. However, administration of β1- or 
β2-adrenergic agonists or antagonists has no effect 
on ACTH or cortisol secretion in the normal adrenal 
gland [23]. Yet, ectopic expression of β-adrenergic 
receptors was reported in vitro in a tumor from a 
patient with CS [24]. Furthermore, increased steroido-
genesis was demonstrated by hypercatecholamines 
evoked by upright posture without ACTH mediation 
in patients with AIMAH and CS [25]. In our patient, 
there was no evidence of catecholamine involvement 
in the pathogenesis of his AIMAH.
The LH receptor normally activates adenylyl cyclase 
and phospholipase C to stimulate steroidogenesis in 
the gonads [26]. The receptor is mainly expressed 
in gonadal tissues, but it is also found in other tis-
sues, including the uterus, fallopian tubes, placenta, 
brain, hypothalamus and prostate [27]. The LH/hCG 
receptor was identified by immunohistochemistry 
in the zona reticularis of the human adrenal [28]. 
Cortisol production is directly controlled by endog-
enous secretion of LH/hCG. The direct involvement 
of this aberrant LH/hCG receptor expression in the 
development of hyperplasia has been demonstrated 
[29]. In our patient, administration of GnRH did not 
stimulate additional cortisol production.
In the normal adrenal gland, 5-HT4 receptor ago- 
nists are potent stimulators of aldosterone secre-
tion but only weakly affect cortisol secretion in vitro. 
In vivo, they normally do not stimulate cortisol pro-
duction [30]. A number of patients with adrenal CS 
were reported to be responsive to oral cisapride or 
meto clopramide (5-HT4 receptor agonist) adminis-
tration. The exag gerated cortisol responses in these 
patients could be secondary to the increased zona 
fasciculate expression or abnormal function of a 
“eutopic” 5-HT4 receptor–effector system [4]. When 
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given orally, metoclopramide did not alter the serum 
cortisol level in our patient.
Our hypothesis is that the ectopic or aberrant 
receptors in adrenal cells under stimulation by trophic 
factors other than ACTH (such as vasopressin) are 
not governed by the negative feedback effects of glu-
cocorticoids and hence hypersecretion of cortisol 
occurs. Another possibility is that chronic stimulation 
by one of these trophic factors besides ACTH leads 
to hyperplasia, nodular formation and eventually 
autonomous hypersecretion from the adrenal cortex 
and the subsequent development of CS.
The treatment of choice for AIMAH is total bilateral 
adrenalectomy, either by the open flank or laparoscopic 
approach. It is the most definitive treatment, although 
lifetime replacement of glucocorticoids is necessary. 
Unilateral adrenalectomy may result in some clinical 
and laboratory improvement, particularly in insulin 
resistance and glycemic control, but persistent hyper-
cortisolism may increase morbidity due to higher 
risks of atherosclerosis, hypertension, diabetes, hyper-
lipidemia, and obesity in affected patients [31,32].
Medical treatment of AIMAH based on the aberrant 
adrenal receptors theory includes administration of 
octreotide for GIP-dependent CS [33], propranolol for 
β-adrenergic receptors [34], and a long-acting GnRH 
agonist for LH-dependent CS [35]. Treatment also 
includes a partial response to OPC-21268, a V1a-
receptor antagonist for vasopressin-responsive CS 
[36]. Ketoconazole, metyrapone and mitotane likewise 
have been shown to be effective in inhibiting steroido-
genesis in some cases of AIMAH with CS [37–39].
We reported a case of CS due to ACTH-independent 
macronodular hyperplasia, an extremely rare cause 
of CS. After challenges with a mixed meal, metoclo-
pramide, GnRH, glucagon and vasopressin, cortisol 
production increased only with vasopressin adminis-
tration. We speculate that the pathophysiologic mech-
anism of CS in this case was due to either an ectopic 
vasopressin effect or hyperactivity of eutopic recep-
tors on the tumor cells.
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